Meta‐analysis: anti‐viral therapy of hepatitis C virus‐related liver disease in renal transplant patients
Authors:
Open Access
- 27 October 2006
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 24 (10) , 1413-1422
Abstract
Summary: Background: The efficacy and safety of interferon‐based therapy in renal transplant recipients with hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue.Aim: To evaluate efficacy and safety of antiviral therapy with interferon (interferon alone or interferon plus ribavirin) in renal transplant patients with hepatitis C by performing a systematic review of the literature with a meta‐analysis of clinical trials.Methods: The primary outcomes were sustained virological response (as a measure of efficacy) and/or drop‐out rate (as a measure of tolerability). We used the random‐effects model of DerSimonian and Laird, with heterogeneity and sensitivity analysis.Results: We identified 12 clinical trials (102 unique patients); there was one controlled study. The summary estimate for sustained virological response and drop‐out rate was 18.0% (95% CI 7.0–29.0%) and 35.0% (95% CI 20–50%), respectively. The most frequent side‐effect requiring interruption of treatment was graft dysfunction (n = 28; 71.7%). Meta‐regression analysis showed an inverse and significant association between reference year and drop‐out logit rate (P = 0.012); an inverse link between sustained virological response logit rate and frequency of hepatitis C virus genotype 1 (P = 0.067) and cirrhosis (P = 0.08) was found, even if no statistical significance was reached. No publication bias was observed.Conclusions: Interferon‐based therapy of hepatitis C has poor tolerance and safety after renal transplant. The optimal treatment of hepatitis C after renal transplant requires additional agents or alternative therapeutic approaches.Keywords
This publication has 49 references indexed in Scilit:
- Efficacy of Interferon-α in the Treatment of Chronic Hepatitis C in Dialysis Patients: Two Therapeutic Protocols ComparedNephron Clinical Practice, 2005
- Effect of Chronic Viral Hepatitis on Graft Survival in Saudi Renal Transplant PatientsNephron Clinical Practice, 2005
- Interferon Therapy in Hemodialysis Patients with Chronic Hepatitis C: Study of Tolerance, Efficacy and Post-Transplantation CourseNephron Clinical Practice, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- A 20-YEAR CASE STUDY OF A KIDNEY TRANSPLANT RECIPIENT WITH CHRONIC ACTIVE HEPATITIS CTransplantation, 1998
- TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1995
- Hepatitis C virus: The nephrologist's viewAmerican Journal of Kidney Diseases, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Controlled Clinical Trial of Prophylactic Human-Leukocyte Interferon in Renal TransplantationNew England Journal of Medicine, 1979